TNF and metabolic dysfunction-associated steatotic liver disease: In addition, none of IBD patients treated with vedolizumab showed NAFLD (n = 0 vs. n = 16 (23%), p = 0.023), while most IBD–NAFLD patients were treated with antitumor necrosis factor-alfa (TNF-α; n = 15 (88%) vs. n = 46 (67%), p = 0.841) and ustekinumab (n = 2 (12%) vs. n = 7 (10%), p = 1.000) but with no statistically significant difference between the two groups.